These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9587133)

  • 1. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant.
    Chadburn A; Chen JM; Hsu DT; Frizzera G; Cesarman E; Garrett TJ; Mears JG; Zangwill SD; Addonizio LJ; Michler RE; Knowles DM
    Cancer; 1998 May; 82(10):1978-87. PubMed ID: 9587133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of p16/INK4a in posttransplantation lymphoproliferative disorders.
    Martin A; Baran-Marzak F; El Mansouri S; Legendre C; Leblond V; Charlotte F; Davi F; Canioni D; Raphaël M
    Am J Pathol; 2000 May; 156(5):1573-9. PubMed ID: 10793069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders.
    Knowles DM; Cesarman E; Chadburn A; Frizzera G; Chen J; Rose EA; Michler RE
    Blood; 1995 Jan; 85(2):552-65. PubMed ID: 7812011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplantation lymphoproliferative disorders in Mexico: an aggressive clonal disease associated with Epstein-Barr virus type A.
    Quintanilla-Martínez L; Lome-Maldonado C; Schwarzmann F; Gredler E; Reyes E; Angeles-Angeles A; Fend F
    Mod Pathol; 1998 Feb; 11(2):200-8. PubMed ID: 9504692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abdominal-pelvic lymphoproliferative disease after lung transplantation: presentation and outcome.
    Hachem RR; Chakinala MM; Yusen RD; Lynch JP; Aloush AA; Patterson GA; Trulock EP
    Transplantation; 2004 Feb; 77(3):431-7. PubMed ID: 14966421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome.
    Cesarman E; Chadburn A; Liu YF; Migliazza A; Dalla-Favera R; Knowles DM
    Blood; 1998 Oct; 92(7):2294-302. PubMed ID: 9746767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus latent membrane protein-1 oncogene deletion in post-transplantation lymphoproliferative disorders.
    Scheinfeld AG; Nador RG; Cesarman E; Chadburn A; Knowles DM
    Am J Pathol; 1997 Sep; 151(3):805-12. PubMed ID: 9284829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome.
    Ben-Ari Z; Amlot P; Lachmanan SR; Tur-Kaspa R; Rolles K; Burroughs AK
    Liver Transpl Surg; 1999 May; 5(3):184-91. PubMed ID: 10226108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
    Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
    Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients.
    Oyama T; Yamamoto K; Asano N; Oshiro A; Suzuki R; Kagami Y; Morishima Y; Takeuchi K; Izumo T; Mori S; Ohshima K; Suzumiya J; Nakamura N; Abe M; Ichimura K; Sato Y; Yoshino T; Naoe T; Shimoyama Y; Kamiya Y; Kinoshita T; Nakamura S
    Clin Cancer Res; 2007 Sep; 13(17):5124-32. PubMed ID: 17785567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathology of posttransplantation lymphoproliferative disorders.
    Chadburn A; Cesarman E; Knowles DM
    Semin Diagn Pathol; 1997 Feb; 14(1):15-26. PubMed ID: 9044506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
    Walker RC; Paya CV; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; Daly RC; McGregor CG
    J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmacytic hyperplasia in age-related Epstein-Barr virus-associated lymphoproliferative disorders: a report of two cases.
    Kojima M; Morita Y; Nakamura N; Shimizu K; Murayama K; Nakamura S
    Pathol Res Pract; 2008; 204(4):267-72. PubMed ID: 18187262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution.
    Lucioni M; Capello D; Riboni R; Ippoliti G; Campana C; Bandiera L; Arcaini L; Rossi D; Cerri M; Dionigi P; Lazzarino M; Magrini U; Viganò M; Gaidano G; Paulli M
    Transplantation; 2006 Oct; 82(8):1013-23. PubMed ID: 17060848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area.
    Cuellar-Rodriguez J; Avery RK; Lard M; Budev M; Gordon SM; Shrestha NK; van Duin D; Oethinger M; Mawhorter SD
    Clin Infect Dis; 2009 Sep; 49(5):710-6. PubMed ID: 19635026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphoproliferative disorders and hematologic malignancies following organ transplantation.
    Ferry JA; Jacobson JO; Conti D; Delmonico F; Harris NL
    Mod Pathol; 1989 Nov; 2(6):583-92. PubMed ID: 2587566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.
    García-Suárez J; de Miguel D; Krsnik I; Bañas H; Arribas I; Burgaleta C
    Am J Hematol; 2005 Dec; 80(4):271-81. PubMed ID: 16315252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features.
    Orazi A; Hromas RA; Neiman RS; Greiner TC; Lee CH; Rubin L; Haskins S; Heerema NA; Gharpure V; Abonour R; Srour EF; Cornetta K
    Am J Clin Pathol; 1997 Apr; 107(4):419-29. PubMed ID: 9124210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.